Veracyte Inc. (VCYT)
Veracyte Inc. (VCYT) Stock Price, Analysis & Data
| Bid | 33.3 |
| Market Cap | 3.59B |
| Revenue (ttm) | 561.9M |
| Net Income (ttm) | 114.48M |
| Beta | 1.94 |
| EPS (ttm) | 1.35 |
| PE Ratio (ttm) | 33.1 |
| Forward PE | 22.93 |
| P/B (ttm) | 2.71 |
| P/S (ttm) | 6.39 |
| Earnings Date | Nov 3, 2026 |
| Ask | 59.52 |
| Volume | 844,232 |
| Avg. Volume (20D) | 1,313,704 |
| Open | 46.55 |
| Previous Close | 46.41 |
| Day's Range | 44.28 - 46.76 |
| 52-Week Range | 28.25 - 60.91 |
| Analyst | Buy |
| Price Target | 55 (23.10%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About VCYT
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nC...
Financial Performance
In 2025, Veracyte's revenue was 517.14M, an increase of 16.01% compared to the previous year's 445.76M. Earnings were 66.35M, an increase of 174.89%.
Financial StatementsAnalyst Forecast
According to 11 analyst ratings, the average rating for VCYT stock is "Buy". The 12-month stock price forecast is 55, which is upside of 23.1% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
